A multifactorial interdisciplinary intervention reduces frailty in older people: randomized trial

The researchers tested whether a multifactorial, interdisciplinary intervention could reverse frailty in people aged 70+ who were already frail. The intervention was individually tailored based on which of five frailty components each participant had:

• Weight loss → dietitian assessment, home-delivered meals, nutritional supplements (high-energy, high-protein drinks) if BMI <18.5 or mid-upper arm circumference below the 10th percentile
• Exhaustion → if depression was present, referral to psychiatrist or psychologist; if social isolation, referral to day activity groups or volunteer telephone contact
• Weakness, slowness, or low energy expenditure → up to 10 home-based physiotherapy sessions over 12 months, plus a home exercise program (the WEBB program – Weight-bearing for Better Balance) prescribed 3–5 times per week
• Additional problems identified during comprehensive geriatric assessment → review by geriatrician, pain management, treatment of chronic diseases, management of urinary incontinence, equipment recommendations

The comparison group received "usual care" – whatever health and aged care services were normally available in the community (GP visits, medical specialists, nursing, allied health, housekeeping, personal care). Australia has universal health insurance, so both groups had access to standard care.

Primary outcomes:

• Frailty status (using the Cardiovascular Health Study criteria – a 0–5 scale where ≥3 = frail)
• Mobility (using the Short Physical Performance Battery, or SPPB – 0–12 scale, higher = better)

Secondary outcomes:

• Disability (Barthel Index)
• Health-related quality of life (EQ-5D)
• Depressive symptoms (Geriatric Depression Scale, short form)
• Hospitalizations and nursing home admissions
• Deaths

• 216 participants completed the study (out of 241 randomized – 90% completion rate)
• Mean age: 83.3 years (SD 5.9)
• 68% women
• Location: Hornsby and Ku-ring-gai local government areas, Sydney, Australia
• Recruited from: older people who had completed treatment through the Division of Rehabilitation and Aged Care Services (DRACS) at Hornsby Ku-ring-gai Health Service
• Inclusion criteria: aged 70+; met ≥3 of 5 CHS frailty criteria (slow gait speed, weak grip strength, exhaustion, low energy expenditure, weight loss); not living in residential aged care; no moderate/severe cognitive impairment (Mini Mental State Exam >18); life expectancy >12 months; not already a DRACS client; not in another physical intervention study
• Frailty severity at baseline: participants were stratified into "frail" (3 criteria) vs "very frail" (4–5 criteria)

• Frailty phenotype: The Cardiovascular Health Study (CHS) criteria – a 5-point scale. One point each for: slow gait speed (time to walk 4 meters, adjusted for sex and height), weak grip strength (hand dynamometer, adjusted for sex and BMI), exhaustion (self-report from CES-D depression scale), low energy expenditure (Minnesota Leisure Time Activity questionnaire, kcal/week below sex-specific cutoffs), and weight loss (self-reported unintentional loss of >4.5 kg in past year, or measured weight loss ≥5% in past year). Score 0–2 = non-frail/pre-frail, 3–5 = frail.
• Mobility: Short Physical Performance Battery (SPPB) – three components: balance (ability to stand in side-by-side, semi-tandem, and tandem positions for 10 seconds each), gait speed (time to walk 4 meters), and chair stands (time to rise from a chair 5 times). Each component scored 0–4, total 0–12. Higher = better.
• Disability: Barthel Index (0–100, higher = more independent in activities of daily living)
• Quality of life: EuroQol-5D (EQ-5D) – a standardized measure of health status across 5 dimensions
• Depression: Geriatric Depression Scale (short form) – 15-item yes/no questionnaire
• Hospitalizations and nursing home admissions: monthly calendars, confirmed by hospital or facility records
• Deaths: verified by hospital records
• Assessment timing: baseline, 3 months, and 12 months
• Blinding: Outcome assessors were "masked to treatment allocation" – they did not know which group participants were in. Inter-rater reliability checks were done at the start and midway through the trial.

Design: Single-center, parallel-group, randomized controlled trial (RCT).

Randomization: Permuted block randomization with block sizes of 4 and 6, randomly arranged within blocks of 10. Two strata: "frail" (3 CHS criteria) and "very frail" (4–5 criteria). A random number sequence was generated using SPSS. Allocation tables were stored off-site, and project personnel not involved in assessment or intervention managed the allocation.

Blinding: Outcome assessors were blinded (masked to group assignment). Participants and intervention providers could not be blinded – participants knew whether they were receiving extra home visits and exercises. This is a common limitation in behavioral interventions.

Duration: 12 months of intervention, with outcome assessment at 3 and 12 months.

Statistical approach: Intention-to-treat analysis (participants analyzed in the groups they were randomized to, regardless of adherence). Between-group differences reported with 95% confidence intervals and p-values. The study was powered to detect a 15% difference in mobility (lower extremity continuous summary performance score) with 80% power at p=0.05, accounting for 15% dropout and 15% non-compliance.

What this design can prove:

• Because of randomization, differences between groups at 12 months can be attributed to the intervention (causality)
• Blinding of outcome assessors reduces bias in measurement
• Intention-to-treat analysis gives a real-world estimate of effectiveness (not just efficacy in perfect compliers)
• The 12-month follow-up captures medium-term effects

What this design cannot prove:

• Cannot determine which specific component of the intervention was most effective (was it the exercise? the nutrition? the medical management? the case coordination?)
• Cannot generalize to people with cognitive impairment (excluded), people in residential care (excluded), or people outside the Sydney region
• Single-center design limits generalizability to other healthcare systems
• No blinding of participants or providers – possible placebo effects or differential attention effects
• No active control group – "usual care" is a weak comparator; participants in the intervention group received more attention and home visits, which alone could produce benefits
• The trial registration was delayed (8% of participants were already randomized at time of registration) – this is a minor methodological concern

Major methodological weaknesses:

• The original co-primary outcome (Timed Up and Go) was dropped early in the study and replaced with SPPB – this change was made after the trial started, which can introduce bias
• Adherence was documented but not reported in detail in the abstract – the authors note that "the major limiting factor... was the limited ability of the participants to adhere with the recommended intervention plan"
• The intervention was highly individualized, making it difficult to replicate exactly

Primary outcome – Frailty (CHS criteria):

• At 12 months, the between-group difference in the proportion classified as frail was 14.7% (95% CI: 2.4% to 27.0%; p = 0.02)
• This means 14.7% fewer people in the intervention group were frail compared to the control group
• The absolute numbers: 216 participants completed the study; the intervention group had a lower proportion meeting ≥3 frailty criteria

Primary outcome – Mobility (SPPB):

• The SPPB score was stable in the intervention group and declined in the control group
• Mean between-group difference at 12 months: 1.44 points (95% CI: 0.80 to 2.07; p < 0.001)
• The SPPB ranges from 0–12; a 1.44-point difference is considered clinically meaningful (minimal clinically important difference is typically 0.5–1.0 points)

Secondary outcomes:

• No major differences between groups for disability (Barthel Index), depressive symptoms (Geriatric Depression Scale), or health-related quality of life (EQ-5D)
• Hospitalizations and nursing home admissions: not significantly different between groups (specific numbers not reported in abstract)
• Deaths: not significantly different (specific numbers not reported in abstract)

Adverse events:

• Few adverse events occurred; those reported were "exercise-associated musculoskeletal symptoms" (e.g., muscle soreness, joint pain from the exercise program)

• Frailty reduction: For every 7 people treated with this intervention for 12 months, roughly 1 additional person would no longer be classified as frail (number needed to treat ≈ 7, based on 14.7% absolute risk reduction)
• Mobility preservation: The intervention group maintained their physical function while the control group declined by about 1.4 SPPB points. To put this in perspective: a 1-point decline on the SPPB is associated with a 10–15% increased risk of hospitalization and mortality in older adults. The 1.44-point difference means the intervention effectively prevented the equivalent of 12–18 months of age-related decline in mobility.
• Practical translation: If you're 83 years old and frail, this intervention doesn't make you "not frail" on average – it shifts the odds. About 15% of people who would have remained frail instead improved enough to drop below the frailty threshold. For mobility, the intervention prevents getting worse rather than making you dramatically better.

What the authors acknowledge:

• Single-center design limits generalizability
• Participants were mostly women (68%) – results may not apply equally to men
• The intervention was complex and individualized – hard to replicate exactly
• Adherence was a challenge; some participants declined specific interventions
• The trial registration was delayed (8% randomized before registration)

What a critical reader would note:

• No active control: The control group got "usual care" but no extra attention. The intervention group received home visits, phone calls, and personalized attention. Some of the benefit could be from the extra social contact and monitoring, not the specific interventions.
• No blinding of participants: People who know they're getting extra treatment may report feeling better (expectancy effects). The frailty measure includes self-reported exhaustion and energy expenditure, which could be biased.
• Primary outcome changed mid-trial: The Timed Up and Go was dropped and replaced with SPPB after the trial started. This is a red flag – researchers should pre-specify all outcomes. The authors say it was because TUG was "not feasible," but this decision could have been influenced by early data.
• Sample size: 216 completers is modest. The confidence interval for frailty reduction is wide (2.4% to 27.0%), meaning the true effect could be small or large.
• Duration: 12 months is good, but we don't know if effects persist after the intervention stops.
• Population: These were people already connected to a rehabilitation service. Results may not apply to frail older adults who are not in the healthcare system.
• No cost data: The intervention involved physiotherapists, dietitians, geriatricians, case conferences, and home visits. This is expensive. Without cost-effectiveness analysis, we don't know if the benefits justify the resources.

For someone running their own n=1 experiment (or for a caregiver/family member helping an older adult):

What to test

• A combined approach: Don't just exercise. Address all frailty components you can identify. The key elements were:
  • Strength and balance exercise (WEBB program – weight-bearing exercises for balance, done 3–5 times per week, progressed over time)
  • Nutritional support (if weight loss is present: high-energy, high-protein supplements or home-delivered meals)
  • Medical optimization (review by a geriatrician or GP for chronic disease management, pain, incontinence)
  • Social engagement (if isolation or depression is present: group activities, volunteer phone calls)
  • Case coordination (someone to oversee all the pieces and adjust the plan)

Minimum meaningful duration

• 12 months – that's what the study used. However, improvements in strength and balance can be seen in 8–12 weeks. The 12-month timeline matters because frailty reversal is slow and requires sustained effort.
• For a self-experiment: try 3 months as a minimum to see if you're on the right track, but expect full effects to take 6–12 months.

What to measure

• Frailty phenotype (self-assess monthly):
  • Gait speed: time to walk 4 meters (about 13 feet) at usual pace. Cutoff for frailty: <0.8 m/s (or about 5 seconds for 4 meters) for most people
  • Grip strength: use a hand dynamometer if available. Cutoffs vary by sex and BMI (roughly <26 kg for men, <16 kg for women)
  • Exhaustion: "I felt that everything I did was an effort" or "I could not get going" for ≥3 days in the past week (from CES-D scale)
  • Weight loss: unintentional loss of >4.5 kg (10 lbs) in the past year
  • Physical activity: Minnesota Leisure Time Activity questionnaire or simply track minutes of walking per week (<383 kcal/week for men, <270 kcal/week for women ≈ frailty cutoff)
• Mobility (monthly):
  • SPPB: time to stand on one foot (tandem), time to walk 4 meters, time to do 5 chair stands. Score 0–12. A positive result = score stays stable or increases over 12 months
• Simple daily measure: How many minutes per day do you walk? How many times can you stand up from a chair without using your arms?

Key confounds to control for

• Illness: Acute illness (colds, infections, hospitalizations) will temporarily worsen frailty measures. Track illness separately.
• Medication changes: New medications (especially sedatives, blood pressure drugs) can affect balance and energy. Log medication changes.
• Seasonal effects: People are less active in winter. Compare same-season data points.
• Social factors: Bereavement, moving house, or family stress can cause weight loss and exhaustion. Note life events.
• Attention effects: If you're doing this as a self-experiment, you can't blind yourself. Be aware that the act of measuring and tracking may itself improve outcomes (Hawthorne effect).
• Regression to the mean: If you start an intervention when you feel particularly frail, some improvement would happen naturally. Measure for 2–4 weeks before starting to establish a baseline.

What a positive result would look like

• Frailty score drops from ≥3 to ≤2 (you no longer meet the frailty threshold)
• SPPB score increases by ≥1 point (or stays stable while you would have expected decline)
• Gait speed improves by ≥0.1 m/s (about 0.5 seconds faster over 4 meters)
• Chair stand time improves (e.g., from unable to do 5 stands to able, or from 20 seconds to 15 seconds)
• Weight stabilizes or reverses (if you had unintentional weight loss, you regain weight or stop losing)
• Energy levels improve (you report "exhaustion" less than 3 days per week)

Important caveat: This study was done in people with an average age of 83 who